Romain Loyaux

Romain Loyaux

Auto-generated profile, based on publicly available information

Romain Loyaux

Department of Biologie et pathologie médicales, Gustave Roussy, Université Paris-Saclay, Villejuif, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DFDavid Fandrei
David Fandrei
JPJean Pegliasco
Jean Pegliasco
FPFlorence Pasquier
Florence Pasquier
NINathalie Ibrahim
Nathalie Ibrahim
MKMaria Kfoury
Maria Kfoury
JMJean Baptiste MICOL
Jean Baptiste MICOL
Purpose: PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D-mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D-mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D-mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53-mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.

18 May 2024 in Pathology
Verified
Journal Article
Closed access
SGSimon Garinet
Simon Garinet
ALAudrey Lupo
Audrey Lupo
TDThomas Denize
Thomas Denize
RLRomain Loyaux
Romain Loyaux
STSarah Timsit
Sarah Timsit
HBHélène Blons
Hélène Blons

16 August 2023 in Clinical Case Reports
Verified
Journal Article
Open access
RLRomain Loyaux
Romain Loyaux
SLSolène Lecolant
Solène Lecolant
LFLeila Cysique Foilan
Leila Cysique Foilan
CPCaroline Pradon
Caroline Pradon
SCSophie Cotteret
Sophie Cotteret
AAAhmadreza Arbab
Ahmadreza Arbab
Key Clinical Message: This is the first case of a promyelocytic sarcoma diagnosed on pleural effusion and exposed the difficulty of demonstrating a leukemic phase in patients with bone diseases, such as Gorham's disease. It also showed that promyelocytic sarcoma can be treated by ATRA/ATO‐based therapy with an efficient and tolerated response. Myeloid sarcoma (MS) is a rare extramedullary tumoral infiltration of immature myeloid cells and can occur in different sites of the body, without leukemic infiltration. A 38‐year‐old woman patient presented at emergency with a pleural effusion, bicytopenias, and Gorham's disease, a very rare bone disorder. In the following days, she worsened with a chylothorax and pancytopenias. Pleural puncture cytologically revealed promyelocytes with Auer rods. Cytogenetic and molecular analyses subsequently confirmed the presence of the t(15:17) translocation. However, no circulating phase of these atypical promyelocytes was found. Similarly, no other origin was identified. We conclude that the patient had a MS of unknown etiology in the form of a pleural effusion with pathological promyelocytes. The patient was treated with a combination of oral all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) with a cytological and molecular remission persisting 3 months after diagnosis. We report here the first case of a promyelocytic MS of pleural origin without concomitant evidence of acute promyelocytic leukemia. We also show the efficacy of ATRA/ATO treatment in this etiology.


3 June 2025
Verified
Other
Open access
DFDavid Fandrei
David Fandrei
JPJean Pegliasco
Jean Pegliasco
FPFlorence Pasquier
Florence Pasquier
NINathalie Ibrahim
Nathalie Ibrahim
MKMaria Kfoury
Maria Kfoury
JMJean Baptiste MICOL
Jean Baptiste MICOL
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders

12 May 2026 in Leukemia
Verified
Journal Article
Closed access
BDBenoit Ducourneau
Benoit Ducourneau
APArnaud Pagès
Arnaud Pagès
SSStéphanie Struski
Stéphanie Struski
MDMatthieu Decamp
Matthieu Decamp
EREmmanuel Raffoux
Emmanuel Raffoux
JMJean Baptiste MICOL
Jean Baptiste MICOL